0.3968  0.016 (4.28%)		07-26 16:00
Open: 0.3766 High: 0.425 Volume: 695,289		Pre. Close: 0.3805 Low: 0.374 Market Cap: 12(M)

Short term
Mid term
Targets	6-month :	0.49	1-year :	0.57
Resists	First :	0.42	Second :	0.49
Pivot price	0.37
Supports	First :	0.37	Second :	0.34
MAs	MA(5) :	0.37	MA(20) :	0.37
	MA(100) :	0.44	MA(250) :	0.67
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	43.6	D(3) :	32.7
RSI	RSI(14): 54
52-week	High :	3.27	Low :	0.25

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RDHL ] has closed below upper band by 20.9%. Bollinger Bands are 22.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.43 - 0.43	0.43 - 0.43
Low:	0.37 - 0.37	0.37 - 0.37
Close:	0.39 - 0.4	0.4 - 0.4

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Tue, 23 Jul 2024
RedHill Biopharma (NASDAQ:RDHL) Shares Pass Below 200 Day Moving Average of $0.54 - Defense World

Tue, 23 Jul 2024
RedHill Biopharma (NASDAQ:RDHL) Earns Hold Rating from Analysts at StockNews.com - Defense World

Mon, 22 Jul 2024
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien - PR Newswire

Mon, 06 May 2024
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - PR Newswire

Mon, 08 Apr 2024
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights - PR Newswire

Mon, 08 Apr 2024
RedHill Biopharma’s Strategic Pivot and Financial Turnaround - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	32 (M)
Held by Insiders	6.85e+009 (%)
Held by Institutions	0 (%)
Shares Short	556 (K)
Shares Short P.Month	0 (K)

EPS	-2.215e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	366.2 %
Operating Margin	-1 %
Return on Assets (ttm)	60.7 %
Return on Equity (ttm)	-15.8 %
Qtrly Rev. Growth	6.53e+006 %
Gross Profit (p.s.)	-26.34
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	4 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-36 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	14.4

Dividend	0
Forward Dividend	491420
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.